IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population

Hidenori Ochi, Daiki Miki, C. Nelson Hayes, Hiromi Abe, Yasufumi Hayashida, Michiaki Kubo, Kazuaki Chayama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A new type III interferon, IFN lambda 4 (IFNL4), and its single-nucleotide polymorphism (SNP) ss469415590 causing a frame shift have been recently reported strongly to affect antiviral therapy for chronic hepatitis C virus (HCV) infection in African and Caucasian populations compared to previously reported IL-28B SNPs rs12979860 and rs8099917. To compare the predictability for treatment outcome among those polymorphisms, we estimated haplotype structure of IFNL4/IL-28B consisting of the three SNPs in 4630 Japanese chronic hepatitis C patients and 1122 healthy controls and then compared their impact on response to pegylated-IFN (PEG-IFN) plus ribavirin (RBV) combined therapy in 903 HCV-1b-infected patients. A total of five haplotypes were identified, although two major haplotypes accounted for >99 % of the variation. The SNPs were tightly linked but not in absolute linkage disequilibrium. We could not find any difference in the predictive impact of any of these three SNPs with regard to susceptibility to HCV and treatment response. However, patients with favourable rs8099917 TT, linked to unfavourable genotypes of ss469415590 and rs12979860, showed poor initial viral response compared with those with all favourable genotypes (P = 0.0022). These findings suggest that, in part, ss469415590 and rs12979860 may have better predictive impact on response to PEG-IFN plus RBV therapy in the Japanese population, especially in patients with any of the minor haplotypes consisting of these SNPs.

Original languageEnglish
Pages (from-to)1297-1306
Number of pages10
JournalJournal of General Virology
Volume95
Issue numberPART 6
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Interleukin-4
Hepacivirus
Haplotypes
Single Nucleotide Polymorphism
Population
Ribavirin
Chronic Hepatitis C
Therapeutics
Genotype
Linkage Disequilibrium
Virus Diseases
Interferons
Antiviral Agents

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

Ochi, Hidenori ; Miki, Daiki ; Nelson Hayes, C. ; Abe, Hiromi ; Hayashida, Yasufumi ; Kubo, Michiaki ; Chayama, Kazuaki. / IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. In: Journal of General Virology. 2014 ; Vol. 95, No. PART 6. pp. 1297-1306.
@article{d3d78b52312e4769b0e8b5842d1ac37b,
title = "IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population",
abstract = "A new type III interferon, IFN lambda 4 (IFNL4), and its single-nucleotide polymorphism (SNP) ss469415590 causing a frame shift have been recently reported strongly to affect antiviral therapy for chronic hepatitis C virus (HCV) infection in African and Caucasian populations compared to previously reported IL-28B SNPs rs12979860 and rs8099917. To compare the predictability for treatment outcome among those polymorphisms, we estimated haplotype structure of IFNL4/IL-28B consisting of the three SNPs in 4630 Japanese chronic hepatitis C patients and 1122 healthy controls and then compared their impact on response to pegylated-IFN (PEG-IFN) plus ribavirin (RBV) combined therapy in 903 HCV-1b-infected patients. A total of five haplotypes were identified, although two major haplotypes accounted for >99 {\%} of the variation. The SNPs were tightly linked but not in absolute linkage disequilibrium. We could not find any difference in the predictive impact of any of these three SNPs with regard to susceptibility to HCV and treatment response. However, patients with favourable rs8099917 TT, linked to unfavourable genotypes of ss469415590 and rs12979860, showed poor initial viral response compared with those with all favourable genotypes (P = 0.0022). These findings suggest that, in part, ss469415590 and rs12979860 may have better predictive impact on response to PEG-IFN plus RBV therapy in the Japanese population, especially in patients with any of the minor haplotypes consisting of these SNPs.",
author = "Hidenori Ochi and Daiki Miki and {Nelson Hayes}, C. and Hiromi Abe and Yasufumi Hayashida and Michiaki Kubo and Kazuaki Chayama",
year = "2014",
month = "1",
day = "1",
doi = "10.1099/vir.0.060103-0",
language = "English",
volume = "95",
pages = "1297--1306",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "PART 6",

}

IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. / Ochi, Hidenori; Miki, Daiki; Nelson Hayes, C.; Abe, Hiromi; Hayashida, Yasufumi; Kubo, Michiaki; Chayama, Kazuaki.

In: Journal of General Virology, Vol. 95, No. PART 6, 01.01.2014, p. 1297-1306.

Research output: Contribution to journalArticle

TY - JOUR

T1 - IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population

AU - Ochi, Hidenori

AU - Miki, Daiki

AU - Nelson Hayes, C.

AU - Abe, Hiromi

AU - Hayashida, Yasufumi

AU - Kubo, Michiaki

AU - Chayama, Kazuaki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A new type III interferon, IFN lambda 4 (IFNL4), and its single-nucleotide polymorphism (SNP) ss469415590 causing a frame shift have been recently reported strongly to affect antiviral therapy for chronic hepatitis C virus (HCV) infection in African and Caucasian populations compared to previously reported IL-28B SNPs rs12979860 and rs8099917. To compare the predictability for treatment outcome among those polymorphisms, we estimated haplotype structure of IFNL4/IL-28B consisting of the three SNPs in 4630 Japanese chronic hepatitis C patients and 1122 healthy controls and then compared their impact on response to pegylated-IFN (PEG-IFN) plus ribavirin (RBV) combined therapy in 903 HCV-1b-infected patients. A total of five haplotypes were identified, although two major haplotypes accounted for >99 % of the variation. The SNPs were tightly linked but not in absolute linkage disequilibrium. We could not find any difference in the predictive impact of any of these three SNPs with regard to susceptibility to HCV and treatment response. However, patients with favourable rs8099917 TT, linked to unfavourable genotypes of ss469415590 and rs12979860, showed poor initial viral response compared with those with all favourable genotypes (P = 0.0022). These findings suggest that, in part, ss469415590 and rs12979860 may have better predictive impact on response to PEG-IFN plus RBV therapy in the Japanese population, especially in patients with any of the minor haplotypes consisting of these SNPs.

AB - A new type III interferon, IFN lambda 4 (IFNL4), and its single-nucleotide polymorphism (SNP) ss469415590 causing a frame shift have been recently reported strongly to affect antiviral therapy for chronic hepatitis C virus (HCV) infection in African and Caucasian populations compared to previously reported IL-28B SNPs rs12979860 and rs8099917. To compare the predictability for treatment outcome among those polymorphisms, we estimated haplotype structure of IFNL4/IL-28B consisting of the three SNPs in 4630 Japanese chronic hepatitis C patients and 1122 healthy controls and then compared their impact on response to pegylated-IFN (PEG-IFN) plus ribavirin (RBV) combined therapy in 903 HCV-1b-infected patients. A total of five haplotypes were identified, although two major haplotypes accounted for >99 % of the variation. The SNPs were tightly linked but not in absolute linkage disequilibrium. We could not find any difference in the predictive impact of any of these three SNPs with regard to susceptibility to HCV and treatment response. However, patients with favourable rs8099917 TT, linked to unfavourable genotypes of ss469415590 and rs12979860, showed poor initial viral response compared with those with all favourable genotypes (P = 0.0022). These findings suggest that, in part, ss469415590 and rs12979860 may have better predictive impact on response to PEG-IFN plus RBV therapy in the Japanese population, especially in patients with any of the minor haplotypes consisting of these SNPs.

UR - http://www.scopus.com/inward/record.url?scp=84900844565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900844565&partnerID=8YFLogxK

U2 - 10.1099/vir.0.060103-0

DO - 10.1099/vir.0.060103-0

M3 - Article

C2 - 24646752

AN - SCOPUS:84900844565

VL - 95

SP - 1297

EP - 1306

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - PART 6

ER -